Percutaneous coronary intervention (PCI) does not reduce the risk of death or heart attack in patients with stable coronary artery disease, even when evaluated over a 25-year period.
These findings, presented at the American Heart Association (AHA) Scientific Sessions 2026, confirm that the landmark COURAGE trial’s initial results hold true decades later.
“The results do not support a routine strategy of early elective PCI to reduce long-term mortality or myocardial infarction in patients with stable coronary artery disease,” said Dr. Neel M. Butala, a cardiology assistant professor at the University of Colorado School of Medicine, who reported the data to Medscape.
The original COURAGE trial, which initially failed to show a benefit for PCI over optimal medical therapy (OMT) after a median follow-up of 4.6 years, has long been a subject of debate. Critics previously suggested that a longer observation period might reveal hidden survival advantages. To test this, researchers analyzed a subset of 959 patients from the Veterans Affairs (VA) health system, representing 42% of the original study population.
Despite the high-risk profile of the VA cohort—which was almost exclusively male—the study found no significant difference in outcomes between the two treatment groups. The hazard ratio for death or myocardial infarction at 25 years was 1.01, with a 95% confidence interval of 0.88 to 1.15. Kaplan-Meier survival curves for both groups remained nearly identical throughout the 15-year median and 25-year maximum follow-up periods.
The study highlights that while the PCI group underwent initial procedures, many patients in the OMT group eventually required revascularization as well. By the end of the study, 50.4% of the PCI group and 53.5% of the OMT group had undergone revascularization. Approximately 46.5% of the OMT group never required the procedure, yet they achieved comparable long-term survival rates.
“COURAGE is a landmark trial that showed what we can and cannot do in the catheterization lab,” said Rasha Al-Lamee, a professor of medicine and interventional medicine specialist at Imperial College Healthcare NHS Trust, during the AHA discussion. She said that the results forced a shift in clinical practice, clarifying that elective PCI for stable disease should be focused on angina control and quality of life rather than extending survival.
The researchers performed detailed stratifications to determine if specific populations, such as diabetic patients, those with multi-vessel disease, or individuals with reduced left ventricular ejection fraction, derived a survival benefit from PCI. No statistically significant differences were observed across any of these subgroups. Dr. Tariq Muhammad Khan, a cardiac surgeon at the Peshawar Institute of Cardiology in Pakistan, offered a nuanced perspective on Facebook regarding the findings. Khan stated.
While some clinicians point to technological advancements in stents and imaging as reasons the original COURAGE findings might be outdated, experts suggest the core message is still valid. Al-Lamee said that while current PCI technology might lower future revascularization rates, the long-term data provides strong evidence to support conservative management.
Related reading